Generic antiepileptic drugs and associated medical resource utilization in the United States

Neurology

Volumn 74, Issue 20, 2010, Pages 1566-1574

  Labiner, D M ^a   Paradis, P E ^b   Manjunath, R ^c   Duh, M S ^d   Lafeuille, M H ^b   Latremouille Viau D ^b   Lefebvre, P ^b   Helmers, S L ^e  

^a UNIVERSITY OF ARIZONA   (United States)

^b GROUPE D ANALYSE   (Canada)

^c GLAXOSMITHKLINE   (United States)

^d ANALYSIS GROUP   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; GENERIC DRUG; PHENYTOIN; PRIMIDONE; ZONISAMIDE;

ADULT; ARTICLE; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; EMERGENCY HEALTH SERVICE; EPILEPSY; FEMALE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; PATIENT CODING; PRESCRIPTION; PRIORITY JOURNAL; RESOURCE MANAGEMENT; RETROSPECTIVE STUDY; UNITED STATES;

EID: 77952517871     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181df091b     Document Type: Article

References (23)

1. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeco-nomics 2003;21:89-103.
2. McManus P, Birkett DJ, Dudley J, Stevens A. Impact of the minimum pricing policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia. Pharmacoepidemiol Drug Saf 2001; 10:295-300.
3. Centers for Medicare and Medicaid Services. Medicare modernization update (2005). Available at: http://www. cms.hhs.gov/mmaupdate/. Accessed December 2008.
4. Besag FM. Is generic prescribing acceptable in epilepsy? Drug Saf 2000;23:173-182.
5. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25:1578-1592.
6. Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepilep-tic drugs? A review of issues. Seizure 2006;15:165-176.
7. Privitera MD. Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr 2008;8:113-117.
8. Sander JW. The use of antiepileptic drugs: principles and practice. Epilepsia 2004;45(suppl 6):28-34.
9. Jacoby A, Baker G, Chadwick D. Natural history of epilepsy and its social-psychological outcomes: findings from a UK community study. Epilepsia 1994;35:17-18.
10. Jacoby A, Baker G, Steen N, Potts P, Chadwick D. The clinical course of epilepsy and its psychosocial correlates: findings from a UK community study. Epilepsia 1996;37: 148-161.
11. LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008;70:2179-2186.
12. LeLorier J, Duh MS, Paradis PE, et al. Economic impact of generic substitution of lamotrigine: projected costs in the United States using findings in a Canadian setting. Curr Med Res Opin 2008;24:1069-1081.
13. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007;48:464-469.
14. Zachry WM, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpa-tient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009;50:493-500.
15. Duh MS, Paradis PE, Latrémouille-Viau D, et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009;72:2122-2129.
16. th edition. Available at: http://www.bmj.com/epidem/epid.html. Accessed January 8, 2009.
17. Sahai H, Khurshid A. Statistics in Epidemiology: Methods, Techniques and Applications. CRC Press LLC; 1995.
18. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in adult managed care population. Epilepsia 2008;49:446-454.
19. Faught E, Duh MS, Weiner JR, Guérin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality. Neurology 2008;71:1572-1578.
20. Hovinga CA, Asato MR, Manjunath R, et al. Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav 2008;13:316-322.
21. Ettinger AB, Manjunath R, Candrilli SD, Davis KL. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav Epub 2008 Nov 24.
22. Manjunath R, Davis KL, Candrilli SD, Ettinger AB. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav Epub 2009 Jan 4.
23. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-457.